← Research status explorer
Peak / Growth axis
Tesamorelin
Also known as: Egrifta
Current research status
Approved Molecule*
Established pharmaceutical ingredient
Preclinical
Phase 1
Phase 2
Phase 3
Approved Molecule*
Overview
Tesamorelin is a GHRH analogue FDA-approved since 2010, marketed as Egrifta, specifically for reducing excess visceral fat in HIV-associated lipodystrophy. That approval does not extend to other populations or to general fat-loss/body-composition use, which remains off-label.
Last reviewed: September 2026
*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.
